The 45 references in paper J. Floege, F. Eitner, Г. Флюге, Ф. Эйтнер (2009) “ИММУНОМОДУЛИРУЮЩАЯ ТЕРАПИЯ ПРИ IgA-НЕФРОПАТИИ – ОБОСНОВАНИЕ И ФАКТЫ // IMMUNOMODULATING THERAPY IN IgA-NEPHROPATHY - DEFINITION AND FACTS” / spz:neicon:nefr:y:2009:i:1:p:21-29

1
Samuels JA, Stnppoh GF, Craig JC et al. Immunosuppressive treatments for immunoglobulin A nephropathy a meta-analysis of randomized controlled trials. Nephrology (Carlton) 2004; 9: 177-185
(check this in PDF content)
2
Emancipator SN. IgA nephropathy: morphologic expression and pathogenesis. Am J Kidney Dis 1994; 23: 451­ 462
(check this in PDF content)
3
Nishie T, Miyaishi O, Azuma H et al. Development of immunoglobulin A nephropathy- like disease in beta-1, 4- galactosyltransferase-l-deficient mice. Am J Pathol 2007;170:
(check this in PDF content)
4
7-456 4. O’Donoghue DJ, Darvill A, Ballardie FW. Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch- Schonlem purpura. J Clin Invest 1991; 88: 1522-1530
(check this in PDF content)
5
Rifai A. IgA nephropathy immune mechanisms beyond IgA mesangial deposition: Kidney Int 2007; 72: 239-241
(check this in PDF content)
6
Tapia E, Franco M, Sanchez-Lozada LG et al. Mycophenolate mofetil prevents artenolopathy and renal injury in subtotal ablation despite persistent hypertension Kidney Int 2003; 63: 994-1002
(check this in PDF content)
7
Floege J. Recurrent IgA nephropathy after renal transplantation. Semm Nephrol 2004; 24: 287-291
(check this in PDF content)
8
Nolm L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999; 70: S56-62
(check this in PDF content)
9
Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy a randomised controlled trial. Lancet 1999; 353: 883-887
(check this in PDF content)
10
Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157­ 163
(check this in PDF content)
11
Shoji T, Nakanishi I, Suzuki A et al. Early treatment with corticosteroids ameliorates protemuna, proferative lesions, and mesangial phenotypic modulation in adult diffuse proliferate IgA nephropathy. Am J Kidney Dis 2000; 35: 194-201
(check this in PDF content)
12
Katafuchi R, Ikeda K, Mizumasa T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41:972-983
(check this in PDF content)
13
Hogg R, Lee J, Nardelli N et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy Report from the Southwest Pediatnc Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1: 457­ 474
(check this in PDF content)
14
Horita Y Tadokoro M, Taura K et al. Prednisolone co­ administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail 2007; 29: 441-446
(check this in PDF content)
15
Kobayashi Y, Hiki Y, Kokubo T et al. Steroid therapy during the early stage of progressive IgA nephropathy A 10- year follow-up study. Nephron 1996; 72: 237-242
(check this in PDF content)
16
Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy results of a 3-year prospective placebo- controlled randomized study: Kidney Int 2004; 65: 1842-1849
(check this in PDF content)
17
Tang S, Leung JC, Chan LY et al. Mycophenolate mofetil alleviates persistent protemuna in IgA nephropathy. Kidney Int 2005; 68: 802-812
(check this in PDF content)
18
Fnsch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-2145
(check this in PDF content)
19
D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semm Nephrol 2004; 24: 179-196
(check this in PDF content)
20
Yoshikawa N, Ito H, Sakai T et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy The Japanese Pediatnc IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999; 10: 101-109
(check this in PDF content)
21
Yoshikawa N, Honda M, lijima K et al. Steroid treatment for severe childhood IgA nephropathy a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1: 511-517
(check this in PDF content)
22
Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
(check this in PDF content)
23
Lou T, Wang C, Chen Z et al. Randomized controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11: 113-116
(check this in PDF content)
24
Kawasaki Y, Hosoya M, Suzuki J et al. Efficacy of multidrug therapy combined with mizoribme in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribme and with methylprednisolone pulse therapy. Am J Nephrol 2004; 24: 576-581
(check this in PDF content)
25
Rasche FM, Keller F, Lepper PM et al. High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow­ up. Clin Exp Immunol 2006; 146: 47-53
(check this in PDF content)
26
Rasche FM, Keller F, von Muller L et al. Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy. J Nephrol 2006; 19: 465-472
(check this in PDF content)
27
Hebert LA, Wilmer WA, Falkenham ME et al. Renoprotection one or many therapies? Kidney Int 2001; 59: 1211-1226
(check this in PDF content)
28
Wilmer WA, Rovm BH, Hebert CJ et al. Management of glomerular proteinuria a commentary. J Am Soc Nephrol 2003; 14: 3217-3232
(check this in PDF content)
29
Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol 2005; 18: 354-361
(check this in PDF content)
30
Ruggenenti P, Perna A, Gherardi G et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Itahano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-1256
(check this in PDF content)
31
Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-ll receptor blocker and angiotensm- converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124
(check this in PDF content)
32
Kanno Y, Okada H, Saruta T et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow­ up. Clin Nephrol 2000; 54: 360-365
(check this in PDF content)
33
Stefanski A, Schmidt KG, Waldherr R et al. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephntis. Kidney Int 1996; 50: 1321­ 1326
(check this in PDF content)
34
Dillon JJ. Angiotensm-converting enzyme inhibitors and angiotensm receptor blockers for IgA nephropathy. Semm Nephrol 2004; 24: 218-224
(check this in PDF content)
35
Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephropathy with ACE inhibitors A randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
(check this in PDF content)
36
Coppo R, Peruzzi L, Amore A et al. IgACE A Placebo- Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors m Children and Young People with IgA Nephropathy and Moderate Proteinuria. J Am Soc Nephrol 2007; 18: 1880­ 1888
(check this in PDF content)
37
Li PK, Leung CB, Chow KM et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47:751-760
(check this in PDF content)
38
Russo D, Minutolo R, Pisani A et al. Coadmmistration of losartan and enalapnl exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25
(check this in PDF content)
39
Courtney A, McNamee PT, Nelson WE et al. Does angiotensm blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 2007; in press
(check this in PDF content)
40
Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and mterstudy variability. J Am Soc Nephrol 1997; 8: 1739-1744
(check this in PDF content)
41
Lee GSL, Choong HL, Chiang GSC et al. Three year randomized controlled trial of dipyndamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 1997; 3: 117-121
(check this in PDF content)
42
Hwang YC, Lee TW, Kim MJ et al. Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone. Korean J Intern Med 2001; 16: 105-109
(check this in PDF content)
43
Carruthers SG, Larochelle P, Haynes RB et al. Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. Cmaj 1993; 149: 289-293
(check this in PDF content)
44
Roccatello D, Ferro M, Coppo R et al. Report on intensive treatment of extracapillary glomerulonephntis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant 1995; 10: 2054-2059
(check this in PDF content)
45
Harper L, Ferreira MA, Howie AJ et al. Treatment of vasculitic IgA nephropathy. J Nephrol 2000; 13: 360-366 Поступила в редакцию 21.10.2008 г. Принята в печать 10.02.2009 г.
(check this in PDF content)